MPS Pharmaa Ltd - Stock Valuation and Financial Performance

BSE: 531686 | NSE: | Pharmaceuticals & Drugs | Small Cap

MPS Pharmaa Share Price

3.21 0.00 0.00%
as on 26-Mar'24 16:00

DeciZen - make an informed investing decision on MPS Pharmaa

M-Cap below 100cr DeciZen not available

MPS Pharmaa stock performance -

mw4me loader
P/E Ratio (SA):
0.00
Market Cap:
6.1 Cr.
52-wk low:
2.1
52-wk high:
3.2

Is MPS Pharmaa Ltd an attractive stock to invest in?

1. Is MPS Pharmaa Ltd a good quality company?

Past 10 year’s financial track record analysis by Moneyworks4me indicates that MPS Pharmaa Ltd is a below average quality company.

2. Is MPS Pharmaa Ltd undervalued or overvalued?

The key valuation ratios of MPS Pharmaa Ltd's currently when compared to its past seem to suggest it is in the Overvalued zone.

3. Is MPS Pharmaa Ltd a good buy now?

The Price Trend analysis by MoneyWorks4Me indicates it is Weak which suggest that the price of MPS Pharmaa Ltd is likely to Fall in the short term. However, please check the rating on Quality and Valuation before investing.

10 Year X-Ray of MPS Pharmaa:

Analysis of Financial Track Record

Data adjusted to bonus, split, extra-ordinary income, rights issue and change in financial year end
Data adjusted to bonus, split, extra-ordinary income, rights issue and change in financial year end

Data adjusted to bonus, split, extra-ordinary income, rights issue and change in financial year end.

Financial track record gives insight into the company's performance on key parameters over the past ten years. MoneyWorks4me’s proprietary colour codes make it easy for retail investors to gauge the company’s past performance.
MPS Pharmaa Ltd has not performed well majority of the past ten years indicating its past ten year financial track record is not good

Value Creation

Value Creation Index Colour Code Guide

Mar'14Mar'15Mar'16Mar'17Mar'18Mar'19Mar'20Mar'21Mar'22Mar'23TTM
ROCE % 4.9%0.3%-4.3%-33.7%-4.8%-7.5%-7.6%-37.3%-1.4%-10.9%-
Value Creation
Index
-0.7-1.0-1.3-3.4-1.4-1.5-1.5-3.7-1.1-1.8-

Growth Parameters

Growth Parameters Colour Code Guide

Sales 30.312.21.42.84.10.800000
Sales YoY Gr.--59.6%-89%110.4%44%-79.7%-100%NANA-100%-
Adj EPS 0.3-0.5-0.6-3.9-0.5-0.7-0.6-2.4-0.1-0.6-0.5
YoY Gr.--245.2%NANANANANANANANA-
BVPS (₹) 11.610.79.96.15.654.42.121.51.2
Adj Net
Profit
0.5-0.7-1.2-7.4-0.9-1.3-1.2-4.5-0.1-1.1-1
Cash Flow from Ops. 4.62.21.30.4-0.30.6-0.5-0.9-4.3-0.9-
Debt/CF from Ops. 1.83.65.317.9-19.510.5-12.8-6.1-1.3-7.8-

CAGR

CAGR Colour Code Guide

9 Years 5 Years 3 Years 1 Years
Sales -100%-100%NA-100%
Adj EPS -206.6%NANANA
BVPS-20.5%-23.7%-30.7%-27%
Share Price -1.9% 11.1% 66.9% 52.9%

Key Financial Parameters

Performance Ratio Colour Code Guide

Mar'14Mar'15Mar'16Mar'17Mar'18Mar'19Mar'20Mar'21Mar'22Mar'23TTM
Return on
Equity %
3-3.4-6.2-48.3-7.7-12.3-13-73.7-3.6-31.8-36
Op. Profit
Mgn %
9.46.6-36.4-242-12.8-86.8-15362.10-2079.40NAN
Net Profit
Mgn %
1.5-5.5-87.9-259.8-21.1-150.5-26692.70-437.30-INF
Debt to
Equity
0.50.50.40.60.60.70.81.41.52.4-
Working Cap
Days
2255324,1131,3006212,6114,39,267023,66000
Cash Conv.
Cycle
1363363,2091,0174131,6512,62,89009,80300

Recent Performance Summary

No data to display

Return on Equity is Poor

Sales growth has been subdued in last 3 years 0.00%

Debt to equity has increased versus last 3 years average to 2.42

Sales growth is not so good in last 4 quarters at 0.00%

Latest Financials - MPS Pharmaa Ltd.

Standalone Consolidated
TTM EPS (₹) -0.5 -
TTM Sales (₹ Cr.) 0 -
BVPS (₹.) 1.2 -
Reserves (₹ Cr.) -17 -
P/BV 2.78 -
PE 0.00 -
From the Market
52 Week Low / High (₹) 2.10 / 3.21
All Time Low / High (₹) 0.32 / 53.25
Market Cap (₹ Cr.) 6.1
Equity (₹ Cr.) 19.1
Face Value (₹) 10
Industry PE 47.8

Management X-Ray of MPS Pharmaa:

Shareholding Pattern

Promoter's Holding & Share Pledging

Pledged *16.0416.0416.0416.0416.0416.0416.0416.0416.0416.04
* Pledged shares as % of Promoter's holding (%)

Event Update

Login/Register to view analysis.

Analyst's Notes

Key Ratios of MPS Pharmaa

Adj EPS (Rs.)

Sales (Cr.)

ROE (%)

ROCE (%)

Profit And Loss

(All Figures are in Crores.)
PARTICULARSMar'14Mar'15Mar'16Mar'17Mar'18Mar'19Mar'20Mar'21Mar'22Mar'23
Sales30.2712.241.352.844.090.83000.030
Operating Expenses 27.4411.431.859.724.621.550.684.130.710.95
Manufacturing Costs0.220.210.180.290.150.050.060.070.060.21
Material Costs26.179.790.418.223.510.82000.050.04
Employee Cost 0.650.780.780.790.650.490.450.400.420.49
Other Costs 0.400.650.470.420.300.180.173.660.180.21
Operating Profit 2.830.81-0.49-6.88-0.53-0.72-0.67-4.13-0.67-0.95
Operating Profit Margin (%) 9.4%6.6%-36.4%-242.0%-12.8%-86.8%-15,422.5%--2,079.4%-
Other Income 0.01000.030.060.020.010.200.260.02
Interest 1.201.080.080000000
Depreciation 0.680.650.620.590.590.590.570.560.510.15
Exceptional Items 0000000000
Profit Before Tax 0.96-0.91-1.20-7.44-1.06-1.29-1.24-4.49-0.93-1.07
Tax 0.50-0.24-0.01-0.06-0.19-0.05-0.07-0.08-0.79-0.02
Profit After Tax 0.46-0.68-1.19-7.39-0.87-1.25-1.17-4.42-0.14-1.05
PAT Margin (%) 1.5%-5.5%-87.8%-259.0%-21.1%-150.0%-26,735.0%--437.0%-
Adjusted EPS (₹)0.3-0.5-0.6-3.9-0.5-0.7-0.6-2.3-0.1-0.6
Dividend Payout Ratio (%)0%0%0%0%0%0%0%0%0%0%

Balance Sheet

(All Figures are in Crores.)
PARTICULARSMar'14Mar'15Mar'16Mar'17Mar'18Mar'19Mar'20Mar'21Mar'22Mar'23

Equity and Liabilities

Shareholders Fund 17.3816.0918.9811.6110.769.538.363.953.832.79
Share Capital 15.0315.0319.1119.1119.1119.1119.1119.1119.1119.11
Reserves 2.351.06-0.13-7.50-8.35-9.58-10.75-15.16-15.29-16.32
Minority Interest0000000000
Debt7.045.953.872.902.902.512.541.935.816.76
Long Term Debt2.991.960.980000000
Short Term Debt4.053.992.902.902.902.512.541.935.816.76
Trade Payables4.483.300.640.360.140.160.150.090.120.20
Others Liabilities 5.927.025.086.065.365.365.375.330.400.43
Total Liabilities 34.8232.3628.5720.9319.1517.5616.4111.3010.1610.19

Fixed Assets

Gross Block21.8116.0916.1516.1616.1616.1616.0515.7115.7215.84
Accumulated Depreciation6.637.898.519.109.6910.2810.7911.0411.5511.70
Net Fixed Assets15.188.217.647.066.475.885.264.684.174.14
CWIP 06.156.155.515.215.435.023.903.423.40
Investments 0.920.920.920.920.920.920.920.540.540.54
Inventories6.807.367.531.130.570.570.570.570.550.50
Trade Receivables8.657.684.274.143.862.612.530.590.030.03
Cash Equivalents 0.050.020.030.060.020.020.010.010.010.01
Others Assets3.222.012.032.112.112.122.091.021.431.57
Total Assets 34.8232.3628.5720.9319.1517.5616.4111.3010.1610.19

Cash Flow

(All Figures are in Crores.)
PARTICULARSMar'14Mar'15Mar'16Mar'17Mar'18Mar'19Mar'20Mar'21Mar'22Mar'23
Cash Flow From Operating Activity 4.622.161.250.37-0.340.60-0.49-0.93-4.34-0.87
PBT 0.96-0.91-1.20-7.43-1.06-1.29-1.24-4.49-0.56-1.05
Adjustment 1.851.750.740.610.620.600.590.580.510.15
Changes in Working Capital 21.321.897.20.11.290.152.98-4.30.04
Tax Paid -0.190-0.180000000
Cash Flow From Investing Activity -6.39-0.44-0.050.630.30-0.210.461.540.46-0.10
Capex -6.40-0.44-0.050.630.30-0.220.050.03-0.01-0.12
Net Investments 00000000.3900
Others 0.0100000.010.411.130.470.02
Cash Flow From Financing Activity 1.72-1.75-1.19-0.980-0.390.03-0.613.880.96
Net Proceeds from Shares 5.6800.970000000
Net Proceeds from Borrowing -5.49-1.04-0.98-0.980-0.390.03-0.613.880.96
Interest Paid -1.16-1.07-0.080000000
Dividend Paid 0000000000
Others 2.690.36-1.100000000
Net Cash Flow -0.05-0.030.010.02-0.040000-0.01
PARTICULARSMar'14Mar'15Mar'16Mar'17Mar'18Mar'19Mar'20Mar'21Mar'22Mar'23
Ratios
ROE (%)3.24-4.03-6.79-48.3-7.74-12.28-13.04-71.73-3.64-31.75
ROCE (%)8.130.59-4.23-33.9-5.91-7.76-8.08-36.9-9.64-11.15
Asset Turnover Ratio0.950.360.040.120.20.050000
PAT to CFO Conversion(x)10.04N/AN/AN/AN/AN/AN/AN/AN/AN/A
Working Capital Days
Receivable Days892431,5925153571,426003,5460
Inventory Days982111,98253176252006,2940
Payable Days511451,758222666007701,304

MPS Pharmaa Ltd Stock News

MPS Pharmaa Ltd FAQs

Company share prices are keep on changing according to the market conditions. The closing price of MPS Pharmaa on 26-Mar-2024 16:00 is ₹3.21.
Market capitalization or market cap is determined by multiplying the current market price of a company's shares with the total number of shares outstanding. As of 26-Mar-2024 16:00 the market cap of MPS Pharmaa stood at ₹6.13.
The latest P/E ratio of MPS Pharmaa as of 26-Mar-2024 16:00 is 0.00.
The latest P/B ratio of MPS Pharmaa as of 26-Mar-2024 16:00 is 2.78.
The 52-week high of MPS Pharmaa is ₹3.21 and the 52-week low is ₹2.10.
The TTM revenue is Trailing Twelve Months sales. The TTM revenue/sales of MPS Pharmaa is ₹0.00 ( Cr.) .

About MPS Pharmaa Ltd

Advik Laboratories has been set up by V K Jain, a qualified production chemist with over 20 years experience in pharmaceutical products.

Advik Laboratories was established in the 1994. It is WHO-GMP certified company that has been set up from the ground level with the avowed objective of achieving USFDA standards of quality.

The company has a technical collaboration with PFC Pharma Focus of Switzerland. It enjoys leadership status at various fronts such as high product quality, a growing range of products, state of the art manufacturing process, competitive pricing and customer service. In addition the company exports a wide range of drugs to the Middle East, South America and Africa.

The product range includes ethical, generic drugs and over the counter drugs (OTC) in various formulations.

With over 60,000 square feet of built-up area, ample developed open space around it, a state-of-the-art manufacturing facility, the ground floor has provisions for the production and in-process control section for the manufacturing of steroidal & non-steroidal formulations, change room for gents & ladies and stores for raw & packing materials. The first floor has provision for the production and in-process control section for the manufacturing of ampicillin and non-ampicillin capsules and dry syrup preparations. The second floor has provision for quality control and about 12000 sq ft area is presently being reserved for the manufacture of injectables & ointments in the second phase.

Advik Laboratories provides pharmaceutical formulations that match the international standards of quality. The facility manufactures a wide range of pharmaceuticals formulations in tablets, capsules and dry syrups.

Products - Under Ethical products, the company manufactures Wibatol, Wibatol-O, Robial, Twosum, Majispa, Arfa Gel, Stibomin and Chewfe-C.

Under generic products, the company manufactures drugs catering segment such as antibacterials, antiallergics, antifungals, analgesic, antipyretic and anti-inflammatory, anti-hypertensives, anthelminthics, anti-malarials, corticosteroids, erectile dysfunction, gastrointestinal agents and sedatives.

Award - Advik Laboratories has received the prestigious Udyog Patra Award from the Government of India in 1999.

Read More Read Less
You have 2 views remaining as a Guest User. To get DeciZen Rating of 3,500+ Stocks based on their Quality, Valuation and Price Trend Login Now
© 2024 The Alchemists Ark Pvt. Ltd. All rights reserved. MoneyWorks4Me ® is a registered trademark of The Alchemists Ark Pvt.Ltd.